Screener
CorMedix CRMD Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by CorMedix in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalents.
The source filing: CorMedix’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001410098-26-000021
| Line item | March 31, 2026 | March 31, 2025 |
|---|---|---|
| Cash and cash equivalents | $178,087 | $66,286 |
| Restricted cash (included in prepaid and other assets) | 656 | - |
| Restricted cash (included in other long-term assets) | 332 | 105 |
| Total cash, cash equivalents and restricted cash | 179,075 | 66,391 |
Item 1. Unaudited Condensed Consolidated Financial Statements.
FAQ
- What is CorMedix's restricted cash?
- CorMedix (CRMD) reported restricted cash of $656K in Q1 2026.
- What is the long-term trend for CorMedix's restricted cash?
- Over 5 years (2020 to 2025), CorMedix's restricted cash has grown at a 11.7% compound annual growth rate (CAGR), from $191.31K to $332K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about CorMedix's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude